Management of relapsed/refractory high-risk neuroblastoma

Learn from leading experts how to integrate immunotherapy-based approaches into individualized treatment plans for patients with high-risk relapsed/refractory neuroblastoma.

This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.

This activity is expired.

CME Information